A lethal cancer knocked down by one-two drug punch

Jun 07, 2009

In the battle against cancer, allies can come from unexpected sources. Research at The Jackson Laboratory has yielded a new approach to treating leukemia, one that targets leukemia-proliferating cells with drugs that are already on the market.

Jackson Adjunct Professor Shaoguang Li, M.D., Ph.D., who now has a laboratory at the University of Massachusetts Medical School in Worcester, led a research team that identified a gene involved with the inflammatory response that could hold the key to treating or even preventing chronic myeloid leukemia (CML), a lethal cancer.

In research published in the journal Nature Genetics, the researchers also showed that an asthma medication for human patients is an effective treatment for CML in mice.

The gene, Alox5, processes essential fatty acids to leukotrienes, which are important agents in the inflammatory response. But according to the researchers, Alox5 has a more sinister side. It is vital to the development and maintenance of cancer stem cells.

Cancer stem cells are slow-dividing cells that are thought to give rise to a variety of cancers, including leukemia, and to be critical for maintaining them. Researchers theorize that cancer stem cells must be targeted for effective treatment of many cancers, but direct evidence is still lacking.

The researchers found that CML did not develop in mice without Alox5 because of impaired function of leukemia stem cells. Also, Alox5 deficiency did not affect normal stem cell function, providing the first clear differentiation between normal and cells.

Li also treated mice with CML with Zileuton, an asthma medication that inhibits the Alox5 inflammation pathway, as well imatinib, commonly known as , the most effective current leukemia medication. Imatinib effectively treated CML, but Zileuton was more effective. The two drugs combined provided an even better therapeutic effect.

The Jackson Laboratory is seeking patent protection on the novel approach to treat CML that Li and colleagues have demonstrated.

The exact mechanism for the Alox5 gene in regulating the function of leukemia stem cells but not normal stem cells needs further study, but it appears that the two types of stem cells employ different pathways for self-renewal and differentiation. The findings provide a new focus of study into how leukemia stem cells are distinct from normal stem cells and how they can be targeted in cancer therapies. A future clinical trial targeting Alox5 will provide the first anti-stem cell strategy in cancer therapy. It is likely that other cancer will have specific pathways that also differentiate them from their normal stem cell counterparts.

Source: Jackson Laboratory

Explore further: New tool to probe cancer's molecular make-up

add to favorites email to friend print save as pdf

Related Stories

UCLA researchers identify leukemia stem cells

May 27, 2008

Stem cell researchers at UCLA have identified a type of leukemia stem cell and uncovered the molecular and genetic mechanisms that cause a normal blood stem cells to become cancerous.

Drug has ability to cure type of leukemia

Oct 03, 2007

In people with chronic myeloid leukemia (CML), the drug Imatinib has been shown to drive cancer into remission, but the disease often returns when treatment is stopped. New research by UC Irvine scientists indicates that ...

Recommended for you

New tool to probe cancer's molecular make-up

21 hours ago

Scientists have shown how to better identify and measure vital molecules that control cell behaviour – paving the way for improved tools for diagnosis, prediction and monitoring of cancer.

Mayo Clinic offers at-home colon cancer test

Aug 26, 2014

Mayo Clinic is taking another step toward making detection of colorectal cancer as convenient as possible, announcing Monday an at-home kit that arrives and is sent back in the mail, stool sample included.

Finding keys to glioblastoma therapeutic resistance

Aug 26, 2014

Researchers at the University of California, San Diego School of Medicine have found one of the keys to why certain glioblastomas – the primary form of a deadly brain cancer – are resistant to drug therapy. The answer ...

No link found between diverticular disease, cancer

Aug 25, 2014

(HealthDay)—Colonic diverticular disease does not appear to be linked to an increased risk of subsequent colorectal cancer (CRC), according to research published in the August issue of Clinical Gastroenterology an ...

User comments : 2

Adjust slider to filter visible comments by rank

Display comments: newest first

JZippy
3 / 5 (2) Jun 07, 2009
Fascinating and exciting. I wish them well in their endeavors.
Birger
5 / 5 (1) Jun 08, 2009
Since these drugs are already on the market, I hope they can be put to clinical use against cancer immediately.